EBS — Emergent BioSolutions Balance Sheet
0.000.00%
- $298.31m
- $862.51m
- $1.04bn
- 68
- 87
- 63
- 85
Annual balance sheet for Emergent BioSolutions, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K/A | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 621 | 576 | 643 | 112 | 99.5 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 272 | 275 | 159 | 191 | 155 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 1,196 | 1,272 | 1,210 | 680 | 599 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 675 | 828 | 837 | 399 | 282 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 2,883 | 2,959 | 3,166 | 1,823 | 1,390 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 385 | 374 | 1,229 | 651 | 162 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 1,436 | 1,340 | 1,779 | 1,174 | 907 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Other Equity | |||||
Total Equity | 1,447 | 1,619 | 1,388 | 649 | 483 |
Total Liabilities & Shareholders' Equity | 2,883 | 2,959 | 3,166 | 1,823 | 1,390 |
Total Common Shares Outstanding |